Xenetic Biosciences, Inc.

Equities

XBIO

US9840156023

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 02:00:01 17/07/2024 am IST			5-day change	1st Jan Change
4.24 ^USD	+1.19%		0.00%	+22.89%

22/05	Xenetic Biosciences, Inc. Announces Management Resignations	CI
22/05	Xenetic Biosciences, Inc. Announces Chief Executive Officer Changes	CI

Xenetic Biosciences plc Appoints Sergeevich Knyazev as Non Executive Director

January 27, 2012 at 04:58 pm IST

Xenetic Biosciences plc announced the appointment to the board of Xenetic of Roman Sergeevich Knyazev as a non-executive director with immediate effect. Mr. Knyazev is a current director of SynBio LLP and Russia Nanotechnology.

Latest news about Xenetic Biosciences, Inc.

Xenetic Biosciences, Inc. Announces Management Resignations	23/05	CI
Xenetic Biosciences, Inc. Announces Chief Executive Officer Changes	23/05	CI
Xenetic Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	10/05	CI
Xenetic Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	22/03	CI
CLS Therapeutics Discloses its Views on Xenetic Biosciences	18/03	CI
Xenetic Biosciences, Inc. Enters into Research Agreement with the University of Virginia for the Advancement of Its DNase-Based Oncology Platform	17/01	CI
Xenetic Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	10/11	CI
Xenetic Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	11/23/11	CI
North American Morning Briefing : Debt-Ceiling -2-	17/23/17	DJ
HC Wainwright Downgrades Xenetic Biosciences to Neutral From Buy	16/23/16	MT
Xenetic Biosciences to Implement 1-for-10 Reverse Split	13/23/13	MT
Xenetic Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	12/23/12	CI
Xenetic Biosciences, The Scripps Research Institute Enter Into Research Collaboration	11/23/11	MT
Xenetic Biosciences, Inc. Announces the Appointment of Jonathan Spicer to its Scientific Advisory Board	16/22/16	CI
Xenetic Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	10/22/10	CI
Xenetic Biosciences, Inc. announced that it has received $0.488835 million in funding from CLS Therapeutics, LLC	13/22/13	CI
Xenetic Biosciences, Inc. announced that it expects to receive $0.488835 million in funding from CLS Therapeutics, LLC	12/22/12	CI
Xenetic Biosciences, Inc. Appoints Allan Tsung, to Its Scientific Advisory Board	04/22/04	CI
Xenetic Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	12/22/12	CI
Xenetic Biosciences, VolitionRx to Develop Adoptive Cell Therapies to Treat Cancer	02/22/02	MT
Xenetic Biosciences Signs Manufacturing Deal With Catalent Unit for Cancer Platform	07/22/07	MT
Xenetic Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	13/22/13	CI
Xenetic Biosciences, Inc. announced that it has received $0.86625 million in funding	04/22/04	CI
HC Wainwright Adjusts Price Target on Xenetic Biosciences to $4 From $5, Reiterates Buy Rating	02/22/02	MT
Xenetic Biosciences, Inc. Enters into Sublicense Agreement with CLS Therapeutics Ltd	27/22/27	CI

Chart Xenetic Biosciences, Inc.

Duration

Period

More charts

Company Profile

Xenetic Biosciences, Inc. is a biopharmaceutical company. The Company is focused on advancing immune-oncology technologies addressing hard to treat cancers. The Company's DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in cancer progression. It is focused on advancing the development of its DNase platform toward a first-in-human, multicenter, dose escalation and dose-expansion study of IV rhDNase I in subjects with locally advanced or metastatic solid tumors. Its systemic DNase program is initially targeting multi-billion-dollar indications including pancreatic cancer, which includes pancreatic ductal adenocarcinoma (PDAC), colorectal carcinoma (CRC) and other gastrointestinal cancers. These are all cancer indications with significant unmet need, and with opportunities for substantial improvement of the available therapeutic options.

Sector

Biotechnology & Medical Research

Calendar

09/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Xenetic Biosciences, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

4.19

Average target price

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
XENETIC BIOSCIENCES, INC.	+22.89%	6.46M
VERTEX PHARMACEUTICALS INCORPORATED	+20.17%	127B
REGENERON PHARMACEUTICALS, INC.	+24.67%	117B
ARGENX SE	+25.44%	27.67B
BIONTECH SE	-17.74%	20.33B
GENMAB A/S	-15.17%	16.79B
BEIGENE, LTD.	-15.21%	15.63B
NEUROCRINE BIOSCIENCES, INC.	+11.91%	14.84B
WUXI APPTEC CO., LTD.	-47.10%	14.65B
SAREPTA THERAPEUTICS, INC.	+54.50%	14.43B

Bio Therapeutic Drugs